Literature DB >> 3122415

Comparison of quantitative ground substance analysis in biopsy and resected tumour in osteosarcomas.

W Kersjes1, U Heise, K Winkler, G Delling.   

Abstract

Osteosarcomas may show variable differentiation. They are divided into osteoblastic, chondroblastic and fibroblastic subgroups depending on their dominant histological differentiation. The pattern of histological differentiation of osteosarcoma is supposed to have an influence on the response to chemotherapy and in this study the relationship between the differentiation of the tumours and response to chemotherapy was examined in 22 osteosarcomas. For this purpose the nuclear size of tumour cells was determined on imprints and the area of the different ground substances on tumour sections after undecalcified preparation. Tumours with little nuclear polymorphism and those with an area of chondroblastic ground substance of more than 20% in the biopsy showed a poor response to chemotherapy. We conclude from our results that lack of nuclear polymorphism and in particular a large area of chondroblastic ground substances in the biopsy, can be regarded as an unfavourable prognostic factor in the response to primary chemotherapy. A comparison of the area of chondroblastic ground substance in biopsy and resection material proves that the biopsy delivers a representative view of the total area of chondroblastic ground substance for the groups of responder and non-responder. Patients with a large amount of chondroblastic ground substance in the biopsy probably require more aggressive chemotherapy.

Entities:  

Mesh:

Year:  1987        PMID: 3122415     DOI: 10.1007/bf00716188

Source DB:  PubMed          Journal:  Virchows Arch A Pathol Anat Histopathol        ISSN: 0174-7398


  13 in total

1.  Osteogenic sarcoma. A follow-up study of the ninety-four cases observed at the Massachusetts General Hospital from 1920 to 1960.

Authors:  M S WEINFELD; H R DUDLEY
Journal:  J Bone Joint Surg Am       Date:  1962-03       Impact factor: 5.284

2.  Osteogenic sarcoma of the jaws and facial bones.

Authors:  L V KRAGH; D C DAHLIN; J B ERICH
Journal:  Am J Surg       Date:  1958-10       Impact factor: 2.565

Review 3.  Pathology of osteosarcoma.

Authors:  D C Dahlin
Journal:  Clin Orthop Relat Res       Date:  1975-09       Impact factor: 4.176

4.  Osteogenic sarcoma. A study of six hundred cases.

Authors:  D C Dahlin; M B Coventry
Journal:  J Bone Joint Surg Am       Date:  1967-01       Impact factor: 5.284

5.  Osteogenic sarcoma. Analysis of factors influencing prognosis in 100 cases.

Authors:  I F Goidanich; L Battaglia; L Lenzi; E Silva
Journal:  Clin Orthop Relat Res       Date:  1966 Sep-Oct       Impact factor: 4.176

6.  Osteosarcoma. A multifactorial clinical and histopathological study with special regard to therapy and survival.

Authors:  S E Larsson; R Lorentzon; H Wedrén; L Boquist
Journal:  Acta Orthop Scand       Date:  1978-12

7.  Morphological grades of regression in osteosarcoma after polychemotherapy - study COSS 80.

Authors:  M Salzer-Kuntschik; G Delling; G Beron; R Sigmund
Journal:  J Cancer Res Clin Oncol       Date:  1983       Impact factor: 4.553

8.  Preoperative chemotherapy for osteogenic sarcoma: selection of postoperative adjuvant chemotherapy based on the response of the primary tumor to preoperative chemotherapy.

Authors:  G Rosen; B Caparros; A G Huvos; C Kosloff; A Nirenberg; A Cacavio; R C Marcove; J M Lane; B Mehta; C Urban
Journal:  Cancer       Date:  1982-03-15       Impact factor: 6.860

9.  Parosteal osteogenic sarcoma.

Authors:  K K Unni; D C Dahlin; J W Beabout; J C Ivins
Journal:  Cancer       Date:  1976-05       Impact factor: 6.860

10.  Nuclear polymorphism in osteosarcomas as a prognostic factor for the effect of chemotherapy. A quantitative study.

Authors:  R Apel; G Delling; H Krumme; K Winkler; M Salzer-Kuntschik
Journal:  Virchows Arch A Pathol Anat Histopathol       Date:  1985
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.